Cancer treatment can be physically, mentally and emotionally taxing.

Patients report disruptions in sleep and physical activity, as well as fatigue and depression.

Strategies to manage or inhibit these treatment related symptoms are few. And research hoping to uncover a biological cause for the symptoms has been limited.

Moffitt Cancer Center researchers having been investigating what may trigger treatment related symptoms in patients with gynaecologic cancers.

In a new study published in the journal Cancers, they evaluated the relationship between inflammatory biomarkers and self-reported treatment related symptoms amongst this patient population.

“What makes our study unique is that it was a controlled comparison. Previous studies have evaluated treatment related symptoms in patients with different cancer types, but ours compared patient reported data with cancer free participant data,” said Aasha Hoogland, Ph.D., lead study author and applied research scientist in the Health Outcomes and Behavior Department at Moffitt.

The study included 121 gynaecologic cancer patients, as well as 105 cancer free participants.

Patients completed assessments and provided blood samples before chemotherapy cycles one, three and six, as well as six and 12 months after treatment.

Cancer free participants were assessed at similar timepoints.

The goal was to examine the longitudinal relationships amongst changes in pro- and anti-inflammatory markers, such as c-reactive protein, TNF-alpha, IL-10, IL-1b, IL-6, IL-1ra, TNFR1 and TNFR2, and treatment related symptoms (fatigue, depression, sleep and physical activity) in women with gynaecologic cancers during and after chemotherapy.

“Specifically, we wanted to know if higher levels of inflammation were associated with worse treatment related symptoms,” Hoogland said. 

Their results showed that fatigue, depression and sleep disturbance were higher amongst the patient population than the cancer free group.

Physical activity was lower in patients before treatment and improved over time.

The researchers determined most of the inflammatory markers were not associated with treatment related symptoms.

However, higher c-reactive protein was associated with greater depression and less physical activity amongst both patients and the cancer free group.

“While this finding was interesting, it suggests there may be other causal mechanisms of treatment related symptoms amongst gynaecologic cancer patients beyond inflammation,” said Heather Jim, Ph.D., study author and co-leader of Moffitt’s Health Outcomes and Behavior Program.

Additional research is needed to identify other biological mechanisms of symptoms and examine whether reductions in inflammation can reduce the severity of symptoms in patients treated with chemotherapy.

Such interventions may considerably improve the quality of life in patients with gynaecologic cancer treated with chemotherapy.

Source: H. Lee Moffitt Cancer Center & Research Institute